It hasn’t been a good week for biotech Amarin (AMRN). On Monday, a District of Nevada judge ruled against the company and in favor of two generic drug makers seeking to establish their own versions of Amarin’s treatment for high triglycerides, Vascepa, thereby, making mincemeat of Amarin’s six patent claims. Judge Du’s ruling caught the Street somewhat by surprise, as it was widely expected Amarin would prevail in the case. Alas, investors were not impressed and on Tuesday, the stock was sent tumbling by a merciless 70%. The next step, naturally, involves an appeal. With this in mind, H.C. Wainwright’s […]